Fulgent Genetics, Inc. FLGT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s cash & equivalents?
- Fulgent Genetics, Inc. (FLGT) reported cash & equivalents of $23.4M in Q1 2026.
- How has Fulgent Genetics, Inc.'s cash & equivalents changed year-over-year?
- Fulgent Genetics, Inc.'s cash & equivalents decreased by 65.2% year-over-year, from $67.28M to $23.4M.
- What is the long-term trend for Fulgent Genetics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s cash & equivalents has grown at a -10.5% compound annual growth rate (CAGR), from $87.43M to $50.19M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.